Home » CEPTOR RETAINS BANYAN BIOMARKERS TO DEVELOP TEST TO EVALUATE EFFECTIVENESS OF MYODUR FOR MUSCULAR DYSTROPHY
CEPTOR RETAINS BANYAN BIOMARKERS TO DEVELOP TEST TO EVALUATE EFFECTIVENESS OF MYODUR FOR MUSCULAR DYSTROPHY
CepTor Corporation, a development-staged biopharmaceutical company focusing
on cell-targeted therapeutic products for neuromuscular and neurodegenerative
diseases, announced that Banyan Biomarkers, Inc. has been retained to identify
a biomarker assay that evaluates the usefulness of Myodur for treating Duchenne
Muscular Dystrophy (DMD) in children. Biomarkers, proteins found in body fluids,
are crucial in determining a drug's efficacy and toxicity and have the potential
to significantly reduce a company's clinical trial costs and duration.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May